Precision Medicine Will Be In Action At ASCO
Executive Summary
Though the tracks and sessions are still named largely for organs and other phenotypic descriptions of cancer, the notion of basing treatments on the molecular drivers of a tumor alone is pervasive at this year’s meeting of the American Society of Clinical Oncology, June 1-5 in Chicago.
You may also be interested in...
Pfizer’s New Head Of Orphan And Genetic Diseases Looks To Shake Up The Big Pharma Problem-Solving Model
Pfizer’s new head of orphan and genetic diseases, Kevin Lee, aims to build a capability within the Big Pharma that is specifically focused on rare diseases, employing a “partner by first intent” problem solving philosophy that reaches across other internal units and across the scientific community.
Quality Of Biomarkers Questioned Again; Lancet Report Calls For Better Evidence
As personalized medicine shifts from theory to practice, concerns are mounting about whether the evidence behind many biomarkers is sufficient to make pharmacogenomic testing worthwhile – suggesting sponsors should pay careful attention to providing evidence to support use of companion diagnostics.